AIM ImmunoTech Inc
AIM1.155USD
-0.055-4.55%
取引時間 （ET）15分遅れの株価
3.20M時価総額
損失額直近12ヶ月PER
詳細情報 AIM ImmunoTech Inc 企業名
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Incの企業情報
企業コードAIM
会社名AIM ImmunoTech Inc
上場日Jul 12, 1996
最高経営責任者「CEO」Equels (Thomas K)
従業員数21
証券種類Ordinary Share
決算期末Jul 12
本社所在地2117 Sw Highway 484
都市OCALA
証券取引所NASDAQ OMX – NASDAQ Basic Amex
国United States of America
郵便番号32801
電話番号13524487797
ウェブサイトhttps://aimimmuno.com/
企業コードAIM
上場日Jul 12, 1996
最高経営責任者「CEO」Equels (Thomas K)
AIM ImmunoTech Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.91K
-15.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-3.00%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-1.00%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
-1.00%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.91K
-15.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-3.00%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-1.00%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
-1.00%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.31%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
他の
94.19%
株主統計
株主統計
比率
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.31%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
他の
94.19%
種類
株主統計
比率
Individual Investor
3.86%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.58%
他の
92.38%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
2023Q3
69
43.37K
10.32%
-1.62K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
DRW Securities, LLC
43.29K
1.52%
+43.29K
--
Sep 30, 2025
Equels (Thomas K)
38.87K
1.36%
-15.00
-0.04%
Oct 24, 2025
Kellner (Theodore D)
37.20K
1.3%
+17.51K
+88.91%
Oct 24, 2025
Sabby Management, LLC
28.86K
1.01%
+28.86K
--
Sep 30, 2025
The Vanguard Group, Inc.
17.50K
0.61%
+17.50K
--
Sep 30, 2025
Deutsch (Todd A)
17.16K
0.6%
--
--
Dec 19, 2024
Geode Capital Management, L.L.C.
16.19K
0.57%
+16.19K
--
Sep 30, 2025
Mitchell (William M)
5.22K
0.18%
-4.00
-0.08%
Oct 24, 2025
Rodino (Peter W III)
4.01K
0.14%
-7.00
-0.17%
Oct 24, 2025
Appelrouth (Stewart L.)
3.89K
0.14%
+670.00
+20.82%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Mar 03, 2025
Merger
100→1
日付
配当落ち日
種類
比率
Mar 03, 2025
Merger
100→1
